X

Trial Profile

FAB LMB 96 -- TREATMENT OF MATURE B-CELL LYMPHOMA/LEUKAEMIA: A SFOP LMB 96/CCG 5961/UKCCSG NHL 9600 COOPERATIVE STUDY.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 18 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cyclophosphamide (Primary) ; Cytarabine; Doxorubicin; Etoposide; Methotrexate; Prednisolone; Prednisone; Vincristine
Indications B-cell lymphoma; Burkitt's lymphoma; Diffuse large B cell lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
Focus Therapeutic Use

Most Recent Events

24 Jul 2014 Biomarkers information updated
27 Mar 2012 Actual patient number changed from 657 to 848 as reported by ClinicalTrials.gov record (NCT00162656).
27 Mar 2012 Actual patient number changed from 657 to 848 as reported by ClinicalTrials.gov record (NCT00162656).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com